Can population BRCA screening be applied in non-Ashkenazi Jewish populations? Experience in Macau population.

Our study shows that testing cost is not the most important factor in considering population BRCA screening, at least for the populations in the developed countries/regions, regardless of the status of mutation prevalence and founder mutation.